Do you want to read an article? Please log in or register.
Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial
Gallbladder and Biliary Diseases
Indications
Related content
Gallbladder and Biliary Diseases
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol
Hirschfield GM, Bowlus CL, Jones DEJ, Kremer AE, Mayo MJ, Tanaka A, Andreone P, Jia J, Jin Q, Macías-Rodríguez RU, Cobitz AR, Currie BM, Gorey C, Lazic I, Podmore D, Ribeiro A, Shannon JB, Swift B, McLaughlin MM, Levy C, GLISTEN Study Group
doi: 10.1016/S2468-1253(25)00192-X
Gastrointestinal Cancer
Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial
Lancet Gastroenterol Hepatol
Tuynman JB, Yao H, Moolenaar LR, Sietses C, Hompes R, Aigner F, Caycedo-Marulanda A, Chen CC, Deeb M, Doornebosch PG, Feng B, Foo CC, Fürst A, Ito M, de Lacy FB, Leão P, Maykel JA, Muratore A, van Oostendorp SE, Park SC, Pędziwiatr M, Ren M, Seitinger G, Stockmann HBAC, Talsma AK, Türler A, Tong W, Wang Q, Xu Q, Zhang H, van Waesberghe JTM, Ali M, Twisk JWR, Zhang Z, de Lacy AM, Hanna GB, Bonjer HJ, COLOR III Study Group
doi: 10.1016/S2468-1253(26)00022-1
Esophagus Diseases
Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
Lancet Gastroenterol Hepatol
Takeuchi H, Machida R, Ando M, Tsubosa Y, Kikuchi H, Kawakubo H, Noma K, Ueno M, Tsushima T, Bamba T, Fujita T, Hamai Y, Kakishita T, Daiko H, Koyanagi K, Matsuda S, Kato K, Sasaki K, Kita R, Kitagawa Y, JCOG1409 investigators
doi: 10.1016/S2468-1253(25)00207-9
Inflammatory Bowel Disease
Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial
Lancet Gastroenterol Hepatol
Pigneur B, Martinez-Vinson C, Bourmaud A, Dabadie A, Duclaux-Loras R, Hugot JP, Roman C, Dumant C, Spyckerelle C, Guinard-Samuel V, Willot S, Dupont C, Breton A, Caron N, Chaillou E, Rebouissoux L, Bertrand V, Triolo V, Pages J, Djeddi D, Bonneton M, Uhlen S, Catteau N, Coopman S, Lepage P, Viala J, Ruemmele FM
doi: 10.1016/S2468-1253(25)00262-6
Gastritis
Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial
Lancet Gastroenterol Hepatol
Gonsalves NP, Dellon ES, Kliewer KL, Shoda T, Yearout R, Aceves SS, Arva NC, Besse JA, Caldwell JM, Chehade M, Coleman A, Collins MH, Anvari S, Falk GW, Gupta SK, Hiremath G, Katzka DA, Khoury P, Leung J, Menard-Katcher C, Menard-Katcher P, Peterson KA, Pletneva MA, Spergel AKR, Spergel JM, Vaysman T, Wechsler JB, Wright BL, Yang GY, Zhang X, Zhou M, Bansal A, Raphael BP, Radwan A, Maloney J, Martin A, Deniz Y, Furuta GT, Martin LJ, Rothenberg ME, Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators
doi: 10.1016/S2468-1253(26)00116-0
Gastrointestinal Cancer
Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial
Lancet Oncol
Sebag-Montefiore D, Adams R, Gollins S, Samuel LM, Glynne-Jones R, Harte R, West N, Quirke P, Sun Myint A, Bach S, Parsons P, Dhadda AS, Brown N, Brown G, Harrison M, Maggs R, Begum R, Chang E, Hackshaw A, Lopes A, ARISTOTLE Trial Management Group and Investigators
doi: 10.1016/S1470-2045(26)00132-4
Gastrointestinal Cancer
Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial
J Clin Oncol
Tang Y, Zhou HT, Xu TZ, Li N, Jiang LM, Jiang J, Lu NN, Li S, Chen SL, Ma HY, Cai Y, Li YH, Zhu Y, He MY, Wang X, Liu K, Zhang HY, Wang J, Zhao T, Li GF, Yang JL, Zhang K, Wang WL, Xiao WW, Chi Y, Yang L, Zhou AP, Zou SM, Fang H, Wang SL, Zhang HZ, Wang XS, Wei LC, Liu SX, Gao YH, Li YX, Hu C, Jin J
doi: 10.1200/JCO-25-02387
Gallbladder and Biliary Diseases
Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial
J Hepatol
Xu Q, Zhou S, Zhang C, Zhou Y, He Y, Jiang Y, Li J, Yi T, Luo C, Zhang L, Wu J, Zhang Y, Wu M, Wei Q, Li Q, Liu B, Chen X, Yao Y, Yu C, Li J, Ren Y, Zhuo W, Yuan L, Li W, Wang ZM, Li B, Xia M, Xie Y, Wu K, Ying J
doi: 10.1016/j.jhep.2026.06.033
Gastrointestinal Cancer
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data
Clin Cancer Res
Campani C, Shim JH, Bouattour M, Touchefeu Y, Delhoume V, Rosmorduc O, Pascale A, An J, Lee HC, Regnault H, Thabut D, Amaddeo G, Ningarhari M, Ollivier-Hourmand I, Métivier C, Ronot M, Ntandaja-Wandji L, Ozenne V, Sidali S, Marra F, Hollande C, Ganne-Carrié N, Nahon P, Peron JM, Lequoy M, Sharma R, Liver Cancer Group P, Allaire M, Nault JC
doi: 10.1158/1078-0432.CCR-25-4943